Proglucagon: difference between revisions
Diff·revision 24 → 25·07:19, 28 Jul 2025
Difference between revision 24 and revision 25 of Proglucagon. 5 lines changed; the page grew by 565 bytes.
| Revision 24 — 02:10, 6 Jul 2025 CiteBot (talk) bot: update parent category chain 6,144 bytes ±0 | Revision 25 — 07:19, 28 Jul 2025 AmylinAmos (talk) convert the receptor-distribution list to a table 6,709 bytes +565 | ||
|---|---|---|---|
| 45 | Because glucagon, GLP-1 and GIP receptors share a common ancestry and their ligands share a common precursor or fold, peptides can be engineered to engage more than one. Tirzepatide engages GIP and GLP-1 receptors; [[Retatrutide|retatrutide]] adds the glucagon receptor; [[Survodutide|survodutide]] engages glucagon and GLP-1 receptors.{{r|campbell2013}} | 45 | Because glucagon, GLP-1 and GIP receptors share a common ancestry and their ligands share a common precursor or fold, peptides can be engineered to engage more than one. Tirzepatide engages GIP and GLP-1 receptors; [[Retatrutide|retatrutide]] adds the glucagon receptor; [[Survodutide|survodutide]] engages glucagon and GLP-1 receptors.{{r|campbell2013}} |
| 46 | 46 | ||
| + | 47 | Adding glucagon-receptor agonism is counter-intuitive, since glucagon raises blood glucose. The rationale is that glucagon-receptor agonism increases energy expenditure and hepatic fat oxidation, and that concurrent GLP-1 agonism more than offsets the glycaemic penalty. The balance between the two is a dose-ratio problem rather than a binary one, and it is the principal design difficulty of the triple agonists.{{r|sandoval2015}} | |
| + | 48 | ||
| 47 | == References == | 49 | == References == |
| 48 | {{reflist}} | 50 | {{reflist}} |
| ⋮ | ⋮ | ||
| 51 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | 53 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> |
| 52 | <ref name="wewer2014">Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. "Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?" ''Diabetologia'' 57(9):1919–1926 (2014). DOI:10.1007/s00125-014-3283-z. PMID 24891019.</ref> | 54 | <ref name="wewer2014">Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. "Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?" ''Diabetologia'' 57(9):1919–1926 (2014). DOI:10.1007/s00125-014-3283-z. PMID 24891019.</ref> |
| + | 55 | ||
| + | 56 | == External links == | |
| + | 57 | * [https://www.ncbi.nlm.nih.gov/gene/2641 GCG — Gene entry] — NCBI Gene record for the proglucagon gene. | |
| 53 | 58 | ||
| 54 | == See also == | 59 | == See also == |